412
Participants
Start Date
May 15, 2023
Primary Completion Date
August 5, 2025
Study Completion Date
August 5, 2025
PLS240
Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
Placebo
Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
Open-Label Extension PLS240
Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Site Number: BGR003-2, Lom
Site Number: BGR001-2, Gabrovo
Site Number: BGR002-2, Rousse
Site Number: BGR004-2, Varna
Site Number: SRB003-2, Belgrade
Site Number: SRB005-2, Belgrade
Site Number: ESP003-2, Córdoba
Site Number: SRB002-2, Niš
Site Number: SRB004-2, Užice
Site Number: USA041-2, Orlando
Site Number: SRB001-2, Kruševac
Site Number: ESP005-2, Manises
Site Number: USA054-2, New Orleans
Site Number: USA043-2, Los Angeles
Site Number: USA039-2, Anaheim
Site Number: USA001-2, Chula Vista
Site Number: USA020-2, Escondido
Site Number: USA042-2, Fresno
Site Number: USA034-2, Fullerton
Site Number: USA046-2, Glendale
Site Number: USA019-2, Granada Hills
Site Number: USA005-2, La Mesa
Site Number: USA044-2, Lancaster
Site Number: USA030-2, Los Angeles
Site Number: USA022-2, Moorpark
Site Number: USA049-2, Northridge
Site Number: USA033-2, Northridge
Site Number: USA003-2, San Diego
Site Number: USA018-2, San Dimas
Site Number: USA056-2, Tarzana
Site Number: USA021-2, Tarzana
Site Number: USA052-2, Victorville
Site Number: USA023-2, Arvada
Site Number: USA031-2, Aurora
Site Number: USA017-2, Middlebury
Site Number: USA015-2, Newark
Site Number: USA004-2, Fort Myers
Site Number: USA002-2, Hollywood
Site Number: USA035-2, South Miami
Site Number: USA013-2, Columbus
Site Number: USA028-2, Mishawaka
Site Number: USA024-2, Wichita
Site Number: USA048-2, Detroit
Site Number: USA025-2, Kalamazoo
Site Number: USA016-2, Minneapolis
Site Number: USA007-2, Amherst
Site Number: USA053-2, Charlotte
Site Number: USA026-2, Durham
Site Number: USA009-2, Toledo
Site Number: USA045-2, Roseburg
Site Number: USA010-2, Greenville
Site Number: USA027-2, Knoxville
Site Number: USA011-2, El Paso
Site Number: USA029-2, Live Oak
Site Number: USA055-2, Prosper
Site Number: USA012-2, San Antonio
Site Number: USA008-2, San Antonio
Site Number: USA006-2, Waxahachie
Site Number: USA038-2, St. George
Site Number: USA051-2, Fairfax
Site Number: USA037-2, Norfolk
Site Number: POL002-2, Poznan
Site Number: POL001-2, Lodz
Site Number: POL004-2, Tomaszów Mazowiecki
Site Number: POL005-2, Warsaw
Site Number: PRT002-2, Covilha
Site Number: PRT001-2, Carnaxide
Site Number: PRT003-2, Lisbon
Lead Sponsor
Collaborators (1)
Launch Therapeutics
UNKNOWN
Pathalys Pharma
INDUSTRY